Castle Biosciences Reports Improved Q1 Net Loss and Strong Test Volume Growth
CSTL sits 69% above its 52-week low of $14.59 on elevated volume (1.9× avg).
Summary
Castle Biosciences reported a significantly improved net loss and strong gross margin in Q1 2026, driven by growth in key test volumes despite a slight revenue decline from a known Medicare coverage issue.
Key Events · Earnings and Guidance · CSTL
-
Net Loss Significantly Improved
The company reported a net loss of $14.5 million for Q1 2026, a substantial improvement compared to a net loss of $25.8 million in Q1 2025.
-
Gross Margin Increased Sharply
Gross margin percentage rose to 72.8% in Q1 2026 from 49.2% in the prior-year period, primarily due to lower amortization of acquired intangible assets.
-
Mixed Revenue Performance with Strong Volume Growth
Total net revenues decreased by 4.9% to $83.7 million, mainly impacted by the loss of Medicare coverage for DecisionDx-SCC. However, overall test report volume increased by 10%, with TissueCypher volumes up 58% and DecisionDx-Melanoma up 16%.
-
Stable Liquidity Position
Cash and cash equivalents, combined with marketable investment securities, totaled $261.7 million as of March 31, 2026, which the company believes is sufficient to fund operations for at least the next 12 months.
Analysis · CSTL · Industrial Applications And Services
Castle Biosciences' Q1 2026 results show a significant improvement in profitability, with net loss narrowing to $14.5 million from $25.8 million in Q1 2025. This improvement is largely driven by a substantial increase in gross margin to 72.8% from 49.2%, primarily due to the full amortization of the IDgenetix test's intangible assets. While total net revenues saw a slight decrease of 4.9% due to the previously disclosed loss of Medicare coverage for the DecisionDx-SCC test, this was partially offset by strong growth in other key tests, particularly TissueCypher (up 58%) and DecisionDx-Melanoma (up 16%), contributing to an overall 10% increase in test report volume. The company maintains a solid liquidity position with $261.7 million in cash and marketable securities, which management believes is sufficient for at least the next 12 months. The CFO's adoption of a Rule 10b5-1 plan to sell a modest number of shares is a routine, pre-planned event. This detailed quarterly report provides comprehensive financial data supporting the preliminary Q1 results announced in a recent 8-K.
At the time of this filing, CSTL was trading at $24.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $749.8M. The 52-week trading range was $14.59 to $44.28. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.